MedTrace Logo

COVID-19 Vaccine Responses in PIDD Subjects

NCT05321407 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-06-03

No results posted yet for this study

Summary

The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.

Conditions

  • X-linked Agammaglobulinemia
  • XLA
  • Primary Immune Deficiency
  • CVID
  • Common Variable Immunodeficiency
  • Primary Antibody Deficiencies
  • Secondary Hypogammaglobulinemia

Sponsors & Collaborators

  • Jeffrey Modell Foundation

    collaborator UNKNOWN

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • University of South Florida

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Duke University

    lead OTHER

Principal Investigators

  • John Sleasman, MD · Duke University

  • Kristina De Paris, PhD · University of North Carolina, Chapel Hill

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2026-06-30
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05321407 on ClinicalTrials.gov